Skip to main content
. 2018 Dec 19;26(2):184–197. doi: 10.1177/1933719118816836

Figure 3.

Figure 3.

Ulipristal acetate regulates solute transporter proteins in 3D myometrial and leiomyoma cells. A, Western blot analysis of myometrial cells exposed to UPA show only a slight increase in AKR1B1 protein at the lowest concentration of 10−10 M (1.34 ± 0.08-fold) when compared to placebo myometrial cells. Higher concentrations of UPA show no change in AKR1B1 expression in these cells from placebo controls. B, Western blot analysis of leiomyoma cells treated with UPA show a decrease in the expression of AKR1B1 at all concentrations: 10−10 M (0.72 ± 0.07-fold), 10−9 M (0.63 ± 0.09-fold), and 10−8 M (0.69 ± 0.07-fold) evaluated. C, Western blot analysis of 3D leiomyoma cells demonstrate a decrease in the expression of SLC5A3 protein at 10−8 M (0.74 ± 0.01), 10−7 M (0.66 ± 0.02), and 10−6 M (0.67 ± 0.05) compared to placebo myometrium, when exposed to UPA treatment (*P < .05). D, Western blot analysis of leiomyoma cells treated with UPA demonstrate a maximally 1.34-fold decrease in the expression of SLC5A3 protein for all concentrations of UPA: 10−10 M (0.80 ± 0.12), 10−9 M (0.84 ± 0.01), 10−8 M (0.83 ± 0.12), and 10−7 M (0.74 ± 0.02) evaluated, that was not concentration dependent. AKR1B1 indicates aldo-keto reductase family 1 member B1; SLC5A3, solute carrier family 5 member 3; UPA, ulipristal acetate.